

MAY 2023

# Investor Update



# Forward-Looking Statements

This presentation, including any oral presentation accompanying it, contains forward-looking statements, including, without limitation, statements related to: Exelixis' commitment to creating long-term, sustainable value for shareholders with a disciplined R&D and capital allocation strategy and leveraging the company's strengths in drug discovery, clinical development and commercialization to advance medicines designed to improve the standard of care for cancer patients and help them to recover stronger and live longer; Exelixis' strategy to expand and defend its successful CABOMETYX franchise, including continued momentum and growth for CABOMETYX in light of data from CheckMate -9ER and aggressive defense of the cabozantinib IP estate, as well as completing enrollment and reporting pivotal top-line data from CONTACT-02 in the second half of 2023 and reporting the next OS analysis from COSMIC-313 by YE 2023; the therapeutic and clinical potential of zanzalintinib, including an optimized PK profile and differentiated adverse event profile, as well as Exelixis' clinical development plans for zanzalintinib, which will be based on Exelixis' experience with cabozantinib and will include the initiation of additional phase 3 studies in 2023; the therapeutic and clinical potential of XB002, including differentiation across all aspects of ADC technology, potential activity beyond that of TIVDAK, a potentially improved adverse event profile versus TIVDAK and the opportunity for broad development, as well as Exelixis' clinical development plans for XB002, including entering XB002 into full development in 2023; Exelixis' belief that zanzalintinib will have worldwide rights with IP protection into the 2040s, and that both zanzalintinib and XB002 will be drivers of revenue growth into the 2030s; Exelixis' strategy for capital- and time-efficient investments in its early-stage pipeline by leveraging its internal capabilities and external network, as well as continuing to supplement the pipeline with early-stage clinical assets through back-end loaded option deals that "pay for success" rather than acquisitions; the therapeutic and clinical potential for ADU-1805 to be a best-in-class mAb targeting SIRPa, including the opportunity for broad development with activity against all human alleles of SIRPa, unlike other SIRPa therapies; Exelixis' belief that execution on its diverse pipeline will lead to the company's next wave of wholly owned cancer drugs and generate long-term growth, with anticipation of multiple pipeline programs progressing to INDs across both biotherapeutics and small molecules; Exelixis' list of anticipated milestones for 2023 and summary of key 2023 corporate objectives; Exelixis' 2023 product revenue guidance for the cabozantinib franchise and 2023 R&D spend guidance for its clinical-stage and drug discovery programs; Exelixis' Board refreshment plans in 2024 and 2025; and other statements that are not historical facts. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis' and its partners' ability to obtain or maintain coverage and reimbursement for these products; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products; the level of costs associated with Exelixis' commercialization, research and development, in-licensing or acquisition of product candidates, and other activities; Exelixis' ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so; the availability of data at the referenced times; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and/or efficacy in clinical testing; uncertainties inherent in the drug discovery and product development process; Exelixis' dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib and other Exelixis product candidates; Exelixis' dependence on third-party vendors for the development, manufacture and supply of its products and product candidates; Exelixis' ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis' marketed products; changes in economic and business conditions, including as a result of the COVID-19 pandemic and other global events; and other factors discussed under the caption "Risk Factors" in Exelixis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 9, 2023, and in Exelixis' future filings with the SEC. All forward-looking statements in this presentation are based on information available to Exelixis as of the date of this presentation, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

## Important Stockholder Information

Exelixis has filed a definitive proxy statement, containing a form of GOLD proxy card, with the SEC in connection with its solicitation of proxies for its 2023 Annual Meeting. THE COMPANY'S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ACCOMPANYING GOLD PROXY CARD AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain a copy of the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC without charge from the SEC's website at: [www.sec.gov](http://www.sec.gov).

The Company, its directors and certain of its executive officers may be deemed to be participants in connection with the solicitation of proxies from the Company's shareholders in connection with the matters to be considered at the 2023 Annual Meeting. Information regarding the ownership of the Company's directors and executive officers in the definitive proxy statement for its 2023 Annual Meeting, filed with the SEC on May 1, 2023, which can be found through the SEC's website at: [www.sec.gov](http://www.sec.gov). Changes to such ownership have been or will be reflected on Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Details concerning the nominees of the Exelixis' Board of Directors for election at the 2023 Annual Meeting are also included in such definitive proxy statement. These documents can be obtained free of charge from the sources indicated above.

# Right Plan to Drive Shareholder Value

---

**Exelixis has a Strong Track Record of Delivering Results for Shareholders**

---

**Disciplined R&D and Capital Allocation Strategy, Leveraging our Strengths to Build Long-Term Value**

---

**Refreshed and Qualified Board**

# Long-Term Strategy and Execution to Create Shareholder Value





# Exelixis: Helping Patients Recover Stronger and Live Longer



## Exelixis Has a History of Success, Driven by People, Values and Investments

- Oncology-focused biotechnology company, **committed to helping cancer patients recover stronger and live longer** through the discovery, development and commercialization of leading cancer therapeutics
- Significant co-funding support from partners / collaborators, with an estimated **60% / \$450M of cabozantinib spend from 2017 – 2022 reimbursed by partners**
- **339% TSR since CABOMETYX's approval in April 2016** vs. 49% and 40% over the same period for the XBI and NBI, respectively <sup>(1)</sup>



## Exelixis Internal R&D Efforts Have Yielded Multiple Approved Products that Improve Standard of Care for Patients

Product	Approved Indications	Partner
 CABOMETYX <sup>®</sup> (cabozantinib) tablets 60 mg / 40 mg / 20 mg	<ul style="list-style-type: none"> <li>▪ Renal Cell Carcinoma (RCC)</li> <li>▪ Hepatocellular Carcinoma</li> <li>▪ Differentiated Thyroid Cancer</li> </ul>	 Outside U.S.
 COMETRIQ <sup>®</sup> (cabozantinib) capsules 50mg and 20mg	<ul style="list-style-type: none"> <li>▪ Medullary Thyroid Cancer</li> </ul>	 Outside U.S.
 COTELLIC <sup>®</sup> (cobimetinib) tablets	<ul style="list-style-type: none"> <li>▪ Advanced Melanoma</li> </ul>	 A Member of the Roche Group
MINNEBRO <sup>®</sup> Tablets	<ul style="list-style-type: none"> <li>▪ Hypertension (Japan)</li> </ul>	



## Cabozantinib Has Been Approved in 68 Countries



**\$1.9B in FY'22 global net product revenue**



**Wholly owned in the United States**



**Development supported by commercial and clinical collaborators**



**Standard of care for the treatment of patients suffering from advanced RCC**

# Our Strategy: Improving the Standard of Care for Cancer Patients Drives Sustainable Value Creation for Shareholders

1

## Expand and Defend Successful CABOMETYX Franchise

- **\$1.9B+** in global net product revenue
- **Continue momentum as the #1 leading TKI for RCC** following practice-changing CheckMate -9ER data in 2021
- **Significant co-funding support from partners / collaborators**, with an estimated 60% / \$450M of cabo spend from 2017 – 2022 reimbursed by partners
- **Aggressively defend IP estate**

2

## Rapidly Advance Wholly Owned Zanzalintinib and XB002



Zanzalintinib and XB002

- **Zanzalintinib currently in two pivotal Phase 3 trials for non-clear cell RCC and CRPC**; additional Phase 3 trials to be initiated in 2023
- **Development plan informed by extensive cabozantinib experience**
- **XB002 to enter full development in 2023, with best-in-class approach based on TIVDAK® experience**
- **Drivers of revenue growth into the 2030s**

3

## Disciplined Investment in Early-Stage Pipeline for Long-Term Growth

### Next-Generation Biotherapeutics and Small Molecules

- **Capital efficient investment strategy** that leverages internal capabilities and a robust external network while avoiding potentially value-destructive scale M&A
- **Back-end loaded option deals** instead of expensive and risky acquisitions **to supplement early-clinical pipeline** (Cybrexa, Sairopa)
- **Biotherapeutics platform enabled by multiple strategic collaborations**
- **In-house small molecule discovery platform based on historic strengths**

# Leveraging Our Success from Cabozantinib with Intentional and Targeted Pipeline Investments




## Our Differentiated Lead Candidates Build on Extensive Target and Asset Validation



**Zanzalintinib  
(XL092)**

***Phase 3** next-generation,  
multi-targeted TKI*

- Worldwide rights with IP protection into 2040s
- Optimized PK and differentiated adverse event profile
- Development program based on cabozantinib experience



**XB002**


***Phase 1** next-generation,  
TF-targeting ADC*

- Validated target with FDA-approved TIVDAK®
- Differentiation across all aspects of ADC technology
- Opportunity for broad development



## Building an Optimized Biotherapeutic and Small Molecule Pipeline

### Biotherapeutics Focus on ADCs and Bispecifics



**XB010  
(5T4 ADC)**

*First custom ADC generated  
through Exelixis'  
collaboration network*




**XB014  
(PD-L1 x CD47  
bsAb)**

**XB628  
(PD-L1 x NKG2a  
bsAb)**

*First bispecific antibodies  
generated through Exelixis'  
collaboration network*

### Small Molecule Focus



**XL102**

***Phase 1** potent, selective  
orally bioavailable  
CDK7 inhibitor*

***Multiple Programs Progressing to INDs***



## Our Clinical-Stage Option Deals Grant Opportunities to “Pay for Success”



**CBX-12**

***Phase 1** novel, first-in-class  
peptide-drug conjugate*

- Exclusive collaboration agreement with Cybrexa with right to acquire CBX-12
- Enhanced delivery of next-generation exatecan payload




**ADU-1805**

***Phase 1** potentially  
best-in-class monoclonal  
antibody targeting SIRPα*

- Exclusive development & option agreement with Sairopa
- Opportunity for broad development with activity against all human alleles of SIRPα, unlike other SIRPα therapies
- Phase 1 initiated in March 2023

# Executing on a Diverse Pipeline to Lead Our Next Wave of Wholly Owned Cancer Drugs and Generate Long-Term Growth



(1) Ipsen has exclusive commercialization rights to cabozantinib outside of the U.S., Canada and Japan. (2) Takeda has exclusive commercialization rights to cabozantinib in Japan.

TKI = tyrosine kinase inhibitor  
TF = tissue factor  
ADC = antibody-drug conjugate

CDK7 = cyclin-dependent kinase 7  
SIRPα = signal-regulatory protein alpha  
OS = overall survival

RCC = renal cell carcinoma  
mCRPC = metastatic castrate  
resistant prostate cancer


CRC = colorectal cancer  
mAb = monoclonal antibody




# Anticipated Milestones for 2023

Program		Milestone
Cabozantinib	<input checked="" type="checkbox"/>	Report top-line results from pivotal trial of cabozantinib + atezolizumab in RCC (CONTACT-03) in 1H 2023
	<input type="checkbox"/>	Complete enrollment and report top-line results in pivotal trial of cabozantinib + atezolizumab in mCRPC (CONTACT-02) in 2H 2023
	<input type="checkbox"/>	Report next overall survival analysis from phase 3 COSMIC-313 pivotal trial evaluating triplet combination of cabozantinib + nivolumab + ipilimumab versus nivolumab + ipilimumab in advanced intermediate- or poor-risk first-line RCC
Zanzalintinib	<input type="checkbox"/>	Initiate multiple new phase 3 pivotal trials evaluating zanzalintinib across indications, tumor types and novel IO combinations
XB002	<input type="checkbox"/>	Accelerate development of XB002 TF ADC, as a monotherapy and in combination with IO and other targeted therapies, across a wide range of tumor types, with goal of moving into full development
	<input type="checkbox"/>	Initiate cohort expansion stage of phase 1 JEWEL-101 study after RD and/or MTD have been determined
	<input type="checkbox"/>	Advance additional combination cohorts to identify sensitive tumor types
XL102	<input type="checkbox"/>	Complete dose escalation, advance phase 1 QUARTZ-101 study into cohort expansion stage and initiate potential combination cohorts
CBX-12 (Cybrexa)	<input type="checkbox"/>	Cybrexa expected to continue to advance phase 1 clinical studies of CBX-12 PDC, including dose-expansion cohorts
ADU-1805 (Sairopa)	<input checked="" type="checkbox"/>	Sairopa to file IND for ADU-1805 SIRPα-targeting monoclonal antibody program in Q1 2023
DCs	<input type="checkbox"/>	Advance XB010 (5T4-targeting ADC), XB014 (PD-L1 x CD47 bsAb) and XB628 (PD-L1 x NKG2A bsAb) biotherapeutic DCs through preclinical and IND-enabling studies in 2023, toward potential IND filings in 2024
Preclinical / Discovery	<input type="checkbox"/>	Advance up to five new development candidates across multiple modalities / mechanisms of small molecules and biologics

# We Have Grown Cabozantinib into a \$1.9B+ Global Annual Sales Franchise Since 2L RCC Approval in 2016




# CABOMETYX Success Relative to Biotech Oncology Launches Since 2016



# Despite ANDA Challenge, Exelixis Shareholders Have Seen Outsized Returns Since CABOMETYX's Approval in 2L RCC

## Exelixis Share Price Performance In Perspective – Since CABOMETYX Approval in 2L RCC (4/25/16)



# Exelixis Has Consistently Outperformed Its Peers and the Broader Biotech Market Across Multiple Time Periods

	Total Shareholder Return						
	From	To	EXELIXIS®	All 2023 Proxy Peers <sup>(1)(3)</sup>	Oncology Peers <sup>(2)(3)</sup>	XBI	NBI
Various Time Periods							
YTD	12/31/22	5/11/23	21%	(3%)	6%	4%	0%
From 6-Months Ago	11/11/22	5/11/23	15%	16%	(4%)	1%	(1%)
From 1-Yr Ago	5/11/22	5/11/23	(2%)	25%	46%	37%	25%
From 3-Yrs Ago	5/11/20	5/11/23	(29%)	11%	(35%)	(17%)	0%
From 5-Yrs Ago	5/11/18	5/11/23	(1%)	8%	(3%)	(6%)	26%
From 10-Yrs Ago	5/11/13	5/11/23	299%	176%	176%	148%	125%
Key Events							
From XBI All-Time High	2/8/21	5/11/23	(19%)	(31%)	(31%)	(51%)	(22%)
From ANDA Submission for Cabo	9/26/19	5/11/23	6%	11%	(29%)	12%	34%
From Cabo RCC Approval	4/25/16	5/11/23	339%	78%	80%	49%	40%
From Cabo METEOR P3 Data in RCC	9/25/15	5/11/23	227%	11%	40%	29%	30%

EXEL outperforms or performs in line with benchmark

EXEL underperforms relative to benchmark



# Our Disciplined Approach to R&D & Capital Planning



# Rigorous Discipline Across All Stages of Drug Development is Fundamental to Our R&D Strategy

Exelixis Assesses Assets Through All Stages of Development to Advance Only the Programs That Meet Our High Bar

## Discovery

- **Disciplined investment with <25% of R&D spend allocated to discovery**
- **Thorough evaluation** to determine if clinical development is warranted
  - High unmet need
  - Mechanistic validation & modality
  - Large market opportunity
  - Alignment with current portfolio

## Early-Stage Clinical

- **Capital-efficient signal seeking studies** to determine patient populations most likely to benefit
- **Rapidly establish dose** to balance safety and efficacy
- **Early evaluation of combination regimens** necessary to improve upon the standard of care
- Assets that do not meet clinical expectations are **quickly discontinued**

## Late-Stage Clinical

- Pivotal trials initiated in the most promising populations **based on proof-of-concept data (whether Ph1b or Ph2)**
- Following approval we continue to invest **in label expansion opportunities** and **move into earlier lines of therapy** (e.g., cabo CheckMate -9ER)

*Our rigorous process has resulted in 19 targets / assets being discontinued at early stages because they did not meet our robust scientific and technical standards*

*Only 2 programs currently in late-stage clinical development (cabo, zanza), both with validated scientific and commercial rationale*

# Cabozantinib's Development Demonstrates Our Approach to R&D, Leveraging Small, Early-Stage Trials to Enable Approval and Rapid Label Expansion



History of Success in Multiple Cabozantinib Pivotal Trials Based on Small, Early-Stage Trials

## Exelixis-Sponsored Cabozantinib Trials


Indication	Early-Stage Signal (N = )	Pivotal Trial	Primary Endpoint	Topline Annc'd
MTC <sup>(1)</sup>	37	EXAM	✓	Oct-11
2L CRPC	315	COMET-1	✗	Sep-14
		COMET-2	✗	Dec-14
2L RCC	25	METEOR	✓	Jul-15
1L RCC		CABOSUN	✓	May-16
2L HCC	41	CELESTIAL	✓	Oct-17
1L RCC	24	Checkmate-9ER	✓	Apr-20
	30	COSMIC-313	✓	Sep-22
2L DTC	15	COSMIC-311	✓	Dec-20
1L HCC	30	COSMIC-312	✓ <sup>(2)</sup>	Jun-21
NSCLC Post-IO	80	CONTACT-01	✗	Dec-22
2L RCC Post-IO	60	CONTACT-03	✗	Mar-23
2L/3L CRPC	160	CONTACT-02	Ongoing	

# Leveraging Collaborators and Partners to Efficiently and Cost-Effectively Advance a Broad Development Effort

## Ongoing Clinical Trials Investigating Exelixis Assets




# Differentiated Lead Clinical Candidates Build on Extensive Target and Asset Validation



## Zanzalintinib (Ph. 3) (MET/VEGFR/AXL/MER)

- ✓ **Next-generation, multi-targeted TKI**
- ✓ Discovered internally; **worldwide rights** with **IP protection into 2040s**
- ✓ **Optimized** PK profile and **differentiated** adverse event profile
- ✓ **Demonstrated activity** in cabozantinib refractory patients
- ✓ **Build on cabo franchise** and develop in indications cabo has shown activity



## XB002 (Ph. 1) (Next-gen TF-targeting ADC)

- ✓ **Validated target** with FDA approved TIVDAK®
- ✓ Acquired **full worldwide rights** at low cost
- ✓ **Differentiation** across all aspects of the ADC (mAb, linker, payload)
- ✓ **Potential activity beyond TIVDAK®**
- ✓ Emerging clinical evidence of **improved adverse event profile** vs. TIVDAK®



# Zanzalintinib: Update on STELLAR-001 ccRCC Expansion Cohort




- ccRCC 2L+ expansion cohort enrollment completed: 32 patients at 100 mg starting dose
- Preliminary efficacy data on-hand for full cohort of prior-ICI treated, including prior-cabo treated and cabo-naïve patients
- With a median follow-up of 7 months:
  - **34%** ORR for the full cohort
  - **50%** ORR for patients who were cabo-naïve
  - 1 unconfirmed PR in the cabo-naïve population; awaiting results of confirmatory scan
- Emerging safety profile continues to look encouraging
- Advancing in multiple P3 trials to maximize commercial opportunity given impact of Inflation Reduction Act

***Data provide evidence for activity of zanza in a cabo-sensitive tumor type & provide additional support for leveraging cabo data to inform the zanza development program***

# Majority of R&D Spend is Dedicated to Advancing Zanzalintinib and Clinical-Stage Programs

EXEL R&D Breakdown (2023E)

- **Majority of R&D spend is dedicated to next-gen clinical-stage programs** (zanzalintinib, XB002, XL102) expected to drive mid- and long-term growth
- **CABOMETYX development is winding down** (two P3 trials remaining) as focus shifts to zanzalintinib and other pipeline



- **<25% of expected 2023 R&D spend is focused on discovery efforts**
- **Highly disciplined early-stage strategy** driven by consistent and thorough evaluations of our portfolio as well as the external landscape / market opportunity
  - A total of 19 targets / assets have been discontinued at early stages since 2018, as they did not meet our robust standards
  - Most recently made the strategic decision to discontinue clinical-stage XL114 (P1, CBM inhibitor)

Other (incl. Dev't)<sup>(1)</sup> CABOMETYX Dev't Manufacturing  
Discovery Stock-Based Comp.

# Optimized Approach to Building a Sustainable Long-Term Pipeline

*Our R&D Strategy Enables Us to Focus on the Most Compelling Science Across Modalities and Platforms*

## Small Molecule Discovery

- Builds upon **historical strength in small molecule chemistry and cancer biology**
- Broadly enabled **internal capabilities and resources**
- **Internally advanced** zanzalintinib, XL102 and 15 additional programs over the last 4 years

## Biotherapeutics

- Advanced primarily through **risk-sharing collaborations**
- **Provides access to compelling assets / technologies** for relatively low upfront economics and resource commitment
- **Capital- and time-efficient** approach to maximize probability of success and build new capabilities

## Clinical Stage Option Deals

- Option structure **minimizes upfront economics prior to asset becoming de-risked**
  - Grants opportunity to only “**pay for success**”
- **Scientifically driven expansion and diversification** of development pipeline, i.e., calculated “*extra shots-on-goal*”




*(Novel peptide-drug conjugate in Phase 1)*




*(Potential best-in-class SIRPa mAb in Phase 1)*

# Exelixis Spends Less Than Comparable Revenue-Generating Oncology Biotechs

2022 R&D Expense (% of Total Revenue)



2018 – 2022 Cumulative R&D Spend (\$B)




# Refreshed and Qualified Board Committed to Value Creation and Governance Best Practices





# Committed to Ongoing Board Refreshment



## Ongoing Commitment to Board Refreshment

Exelixis' Board is exceptionally qualified, with some of the industry's best scientific, financial and commercial minds and specialized expertise in disciplines that are priority areas for the business.

The Board is committed to ongoing refreshment and has pledged to replace two directors, one in each of the next two years, with two new independent directors. By the end of 2025, we will have added six new independent directors in four years.

Our recent and ongoing refreshment underscores our commitment to upholding best-in-class corporate governance to ensure the right balance of skills and expertise to guide the Company's continued evolution and long-term strategic plan.

# Ongoing Collaboration with Key Stakeholders to Advance Our Shared Goals



## ✓ Robust shareholder outreach program

- Exelixis engages with shareholders on a consistent basis to seek feedback on all areas in the business, particularly on issues of corporate governance
  - Bi-annually we request engagement meetings with our top institutional shareholders, representing **65%+** of outstanding shares
  - We accept **100%** of engagement meetings from our top shareholders
- Members of Exelixis' board and senior management involved in engagements, including:
  - **Stelios Papadopoulos** (*Chairman*), **Michael Morrissey** (*CEO*), **Chris Senner** (*CFO*), **Peter Lamb** (*CSO*), **Jeff Hessekiel** (*EVP, General Counsel*), **Susan Hubbard** (*EVP, IR*), **Andrew Peters** (*SVP, Strategy*), **Nina Ayer** (*VP, Corporate Legal Affairs*)

## ✓ Uniformly positive feedback from shareholders on ESG issues

- Published inaugural Corporate Values & Sustainability report in 2022, highlighting our commitment to DEI and ESG initiatives and our achievements in these areas

### ✓ Healthcare Providers

Methods: Industry conferences, forums  
Outcomes: Goal achievement, collaboration

### ✓ Patient Advocacy

Methods: Conferences, sponsorships / grants  
Outcomes: Community inclusion, education

### ✓ Local Communities

Methods: Employee giving / volunteer programs  
Outcomes: Community support and engagement

### ✓ Employees

Methods: Ethics helpline, professional development  
Outcomes: Employee retention / engagement

### ✓ Legislators / Regulators

Methods: Congressional briefings, direct lobbying  
Outcomes: Improve public policies; educate legislators

# Executive Compensation Program Aligned with Shareholder Interests

## Key Compensation Practices


### What We Do

- ✓ Emphasis on pay-for-performance
- ✓ Align compensation with stock price returns
- ✓ Meaningful stock ownership guidelines
- ✓ Performance-based bonus caps
- ✓ Recoupment (clawback) policy
- ✓ Shareholders supportive of advisory Say-on-Pay votes at last 3 AGMs (98% average vote support)


### What We Don't Do

- ✓ No separate change in control agreements
- ✓ No repricing of underwater stock options
- ✓ No special perquisites to NEOs
- ✓ No hedging / margin loans for executives / directors

## CEO PAY MIX



## NEO PAY MIX



Long-Term Incentives	<ul style="list-style-type: none"><li>Promotes alignment of executive decisions with Company goals and shareholder interests</li><li>Annual grant mix of ~50% PSUs and ~50% RSUs to provide a balance between retention and performance<ul style="list-style-type: none"><li>PSUs pay out based on TSR relative to the Nasdaq Biotechnology Index ("NBI") measured over a 3-year period</li><li><b>Over 40% of CEO pay is tied to Exelixis TSR performance related to the NBI</b></li></ul></li><li>Following positive top-line results for PFS endpoint in the COSMIC-313 trial, the Comp. Committee certified the threshold achievement of 2020 PSU grant #1, representing 50% of target number of shares subject to the award</li></ul>
Performance-Base Annual Cash Incentive	<ul style="list-style-type: none"><li>Rewards NEOs for overall corporate performance and contributions toward critical business objectives</li><li>Deliberate corporate goal development and weighting across key business-relevant categories:<ul style="list-style-type: none"><li>(1) Discovery, (2) business development, (3) product development, (4) commercial, and (5) finance, legal and business operations</li></ul></li><li><b>Maximum payout of 150% target bonus opportunity; in 2022, bonuses were paid at 100% of target</b></li></ul>
Base Salary	<ul style="list-style-type: none"><li>Provide an appropriate and competitive base level of current cash income for NEOs</li></ul>

